Antiplatelet therapy in type 2 diabetes mellitus

Current Opinion in Endocrinology, Diabetes and Obesity

Volumn 14, Issue 2, 2007, Pages 124-131

  Angiolillo, Dominick J ^a,b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF FLORIDA   (United States)

Author keywords

Aspirin; Clopidogrel; Diabetes mellitus; Platelets

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ADENOSINE TRIPHOSPHATE; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; GLUCOSE; GLUCOSE TRANSPORTER 4; INSULIN; LAMIFIBAN; LOW DENSITY LIPOPROTEIN; METOPROLOL; PROTEIN KINASE C; PURINE P2Y13 RECEPTOR; PURINERGIC RECEPTOR BLOCKING AGENT; THROMBOXANE; TICLOPIDINE; TIROFIBAN; WARFARIN;

ACUTE CORONARY SYNDROME; ANTICOAGULANT THERAPY; ARTERY THROMBOSIS; BLEEDING; CELL LEVEL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETIC RETINOPATHY; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG ERUPTION; DRUG MECHANISM; DRUG POTENCY; ENDOTHELIAL DYSFUNCTION; ENTERIC COATED TABLET; GASTROINTESTINAL SYMPTOM; GLUCOSE METABOLISM; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; LOW DRUG DOSE; META ANALYSIS; MICROANEURYSM; MONOTHERAPY; MORBIDITY; MORTALITY; NEUTROPENIA; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PERCUTANEOUS CORONARY INTERVENTION; PRIMARY PREVENTION; REVIEW; RISK REDUCTION; SECONDARY PREVENTION; SYSTEMATIC REVIEW; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; THROMBOCYTOPENIA; THROMBOSIS PREVENTION; UNSTABLE ANGINA PECTORIS;

ATHEROSCLEROSIS; DIABETES MELLITUS, TYPE 2; HUMANS; PLATELET AGGREGATION INHIBITORS; RISK FACTORS; THROMBOSIS;

EID: 33847668393     PISSN: 1752296X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MED.0b013e32807f2ad9     Document Type: Review

References (75)

1. American Diabetes Association. Role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. Diabetes Care 1989; 12:573-579.
2. King H, Aubert RE, Herman WH. Global burden of diabetes, 1995-2025: prevalence, numerical estimates, and projections. Diabetes Care 1998; 21:1414-1431.
3. Laakso MLS. Epidemiology of macrovascular disease in diabetes. Diabetes Rev 1997; 5:294-315.
4. Haffner SM, Lehto S, Ronnema T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339:229-234.
5. Stein B, Weintraub WS, Gebhart SP, et al. Influence of diabetes mellitus on early and late outcome after percutaneous coronary angioplasty. Circulation 1995; 91:979-989.
6. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002; 324:71-86.
7. Nesto RW. Correlation between cardiovascular disease and diabetes mellitus: current concepts. Am J Med 2004; 116 (Suppl 5A):11S-22S.
8. Colwell JA, Nesto RW. The platelet in diabetes: focus on prevention of ischemic events. Diabetes Care 2003; 26:2181-2188.
9. Vinik AI, Erbas T, Park TS, et al. Platelet dysfunction in type 2 diabetes. Diabetes Care 2001; 24:1476-1485.
10. Ferroni P, Basili S, Falco A, Davi G. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost 2004; 2:1282-1291.
11. Davi G, Gresele P, Violi F, et al. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. Circulation 1997; 96:69-75.
12. Davi G, Ciabattoni G, Consoli A, et al. In vivo formation of 8-iso-prostaglandin F2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 1999; 99:224-229.
13. Davi G, Catalano I, Averna M, et al. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 1990; 322:1769-1774.
14. Gresele P, Guglielmini G, De Angelis M, et al. Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. J Am Coll Cardiol 2003; 41:1013-1020.
15. Assert R, Scherk G, Bumbure A, et al. Regulation of protein kinase C by short term hyperglycaemia in human platelets in vivo and in vitro. Diabetologia 2001; 44:188-195.
16. Li Y, Woo W, Bose R. Platelet hyperactivity and abnormal Ca(2+) homeostasis in diabetes mellitus. Am J Pysiol Heart Circ Pysiol 2001; 280:H1480-H1489.
17. Valles J, Santos MT, Aznar J, et al. Modulatory effect of erythrocytes on the platelet reactivity to collagen in IDDM patients. Diabetes 1997; 46:1047-1053.
18. Kobayashi K, Watanabe J, Umeda F, Nawata H. Glycation accelerates the oxidation of low density lipoprotein by copper ions. Endocr J 1995; 42:461-465.
19. Millican SA, Schultz D, Bagga M, et al. Glucose-modified low density lipoprotein enhances human monocyte chemotaxis. Free Rad Res 1998; 28:533-542.
20. Ferretti G, Rabini RA, Bacchetti T, et al. Glycated low density lipoproteins-modify platelet properties: a compositional and functional study. J Clin Endocrinol Metab 2002; 87:2180-2184.
21. Falcon C, Pfliegler G, Deckmyn H, Vermylen J. The platelet insulin receptor: detection, partial characterization, and search for a function. Biochem Biophys Res Commun 1988; 157:1190-1196.
22. Ferreira IA, Mocking AI, Feijge MA, et al. Platelet inhibition by insulin is absent in type 2 diabetes mellitus. Arterioscler Thromb Vasc Biol 2006; 26:417-422.
23. 2+ mobilization by insulin via the inhibitory G-protein Gi. J Biol Chem 2004; 279:3254-3264.
24. Ha H, Lee HB. Oxidative stress in diabetic nephropathy: basic and clinical information. Curr Diab Rep 2001; 1:282-287.
25. Patrono C, FitzGerald GA. Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. Arterioscler Thromb Vasc Biol 1997; 17:2309-2315.
26. Davi G, Falco A, Patrono C. Determinants of F2-isoprostane biosynthesis and inhibition in man. Chem Phys Lipids 2004; 128:149-163.
27. Pratico D, Smyth EM, Violi F, Fitzgerald GA. Local amplification of platelet function by 8-iso-PGF2a is not mediated by thromboxane receptor isoforms. J Biol Chem 1996; 271:14916-14924.
28. Minuz P, Andrioli G, Degan M, et al. The Fa-isoprostane 8-epi prostaglandin F2a increases platelet adhesion and reduces the antiadhesive and antiaggregatory effects of NO. Arterioscler Thromb Vasc Biol 1998; 18:1248-1256.
29. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med 1999; 340:115-126.
30. De Vriese AS, Verbeuren TJ, Van de Voorde J, et al. Endothelial dysfunction in diabetes. Br J Pharmacol 2000; 130:963-974.
31. Kario K, Matsuo T, Kobayashi H, et al. Activation of tissue factor-induced coagulation and endothelial cell dysfunction in noninsulin-dependent diabetic patients with microalbuminuria. Arterioscler Thromb Vasc Biol 1995; 15:1114-1120.
32. De Cristofaro R, Rocca B, Vitacolonna E, et al. Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus. J Thromb Haemost 2003; 1:250-256.
33. Duffy B, Bhatt DL. Antiplatelet agents in patients undergoing percutaneous coronary intervention: how many and how much? Am J Cardiovasc Drugs 2005; 5:307-318.
34. Patrono C, Garcia Rodriguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353:2373-2383.
35. Wallentin LC. Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. Research Group on Instability in Coronary Artery Disease in Southeast Sweden. J Am Coll Cardiol 1991; 18:1587-1593.
36. Chew DP, Bhatt DL, Sapp S, Topol EJ. Increased mortality with oral platelet glycoprotein IIb/IIIa antagonists: a meta-analysis of phase III multicenter randomized trials. Circulation 2001; 103:201-206.
37. Nagakawa Y, Akedo Y, Orimo H, Yano H. Effect of the combination of antiplatelet agents in man: combination of aspirin, trapidil, ticlopidine and dipyridamole. Thromb Res 1990; 60:469-475.
38. Savi P, Herbert JM. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost 2005; 31:174-183.
39. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. Stent Anticoagulation Restenosis Study Investigators. N Engl J Med 1998; 339:1665-1671.
40. Urban P, Macaya C, Rupprecht HJ, et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the multicenter aspirin and ticlopidine trial after intracoronary stenting (MATTIS). Circulation 1998; 98:2126-2132.
41. Bertrand ME, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting. The full anticoagulation versus aspirin and ticlopidine (fantastic) study. Circulation 1998; 98:1597-1603.
42. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996; 334:1084-1089.
43. Bertrand ME, Rupprecht HJ, Urban P, Gershlick AH. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the clopidogrel aspirin stent international cooperative study (CLASSICS). Circulation 2000; 102:624-629.
44. Cadroy Y, Bossavy JP, Thalamas C, et al. Early potent antithrombotic effect with combined aspirin and a loading dose of clopidogrel on experimental arterial thrombogenesis in humans. Circulation 2000; 101:2823-2828.
45. Bhatt DL, Bertrand ME, Berger PB, et al. Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol 2002; 39:9-14.
46. Yusuf S, Zhao F, Mehta SR, et al. Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345:494-502.
47. Mehta SR, Yusuf S, Peters RJ, et al. Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358:527-533.
48. Steinhubl SR, Berger PB, Mann JT 3rd, et al., CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial (CREDO). JAMA 2002; 288:2411-2420.
49. American Diabetes Association. Aspirin therapy in diabetes (Position Statement). Diabetes Care 2003; 26 (Suppl 1):S87-S88.
50. Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases (AHA Scientific Statement). Circulation 2002; 106:388-391.
51. Collaborative Group of the Primary Prevention Project: Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomized trial in general practice. Lancet 2001; 357:89-95.
52. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989; 321:129-135.
53. ETDRS Investigators. Aspirin effects on mortality and morbidity in patients with diabetes mellitus. JAMA 1992; 268:1292-1300.
54. Hansson L, Zanchetti A, Carruthers SG, et al., for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 1998; 351:1755-1762.
55. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308:81-106.
56. TIMAD Study Group. Ticlopidine treatment reduces the progression of non-proliferative diabetic retinopathy. Arch Ophthalmol 1990; 108:1577-1583.
57. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348:1329-1339.
58. Bhatt D, Marso S, Hirsch A, et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002; 90:625-628.
59. Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 2006; 27:647-654.
60. Watala C, Golanski J, Pluta J, et al. Reduced sensitivity of platelets from type 2 diabetic patients to acetylsalicylic acid (aspirin)-its relation to metabolic control. Thromb Res 2004; 113:101-113.
61. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005; 54:2430-2435.
62. Angiolillo DJ, Bernardo E, Ramirez C, et al. Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. J Am Coll Cardiol 2006; 48:298-304.
63. Angiolillo DJ, Shoemaker SB, Desai B, et al. A randomized comparison of a high clopidogrel maintenance dose in patients with diabetes mellitus and coronary artery disease: results of the OPTIMUS (Optimizing anti-Platelet Therapy In diabetes MellitUS) study. Circulation (in press).
64. Braunwald E, Antman EM, Beasley JW, et al. American College of Cardiology; American Heart Association. Committee on the Management of Patients With Unstable Angina. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J Am Coll Cardiol 2002; 40:1366-1374.
65. Peters RJ, Mehta SR, Fox KA, et al. Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. Circulation 2003; 108:1682-1687.
66. Sabatine MS, Cannon CP, Gibson CM, et al. Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. CLARITY-TIMI 28 Investigators. N Engl J Med 2005; 352:1179-1189.
67. Chen ZM, Jiang LX, Chen YP, et al., COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005; 366:1607-1621.
68. Sabatine MS, Cannon CP, Gibson CM, et al., Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 2005; 294:1224-1232.
69. Bhatt DL, Fox KA, Hacke W, et al., Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization,Management, and Avoidance (CHARISMA) Investigators. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006; 354:1706-1717.
70. Roffi M, Chew DP, Mukherjee D, et al. Platelet glycoprotein IIb/IIIa inhibitors reduce mortality in diabetic patients with non-ST-segment-elevation acute coronary syndromes. Circulation 2001; 104:2767-2771.
71. Mehilli J, Kastrati A, Schuhlen H, et al. Intracoronary Stenting and Antithrombotic Regimen: Is Abciximab a Superior Way to Eliminate Elevated Thrombotic Risk in Diabetics (ISAR-SWEET) Study Investigators. Randomized clinical trial of abciximab in diabetic patients undergoing elective percutaneous coronary interventions after treatment with a high loading dose of clopidogrel. Circulation 2004; 110:3627-3635.
72. Kastrati A, Mehilli J, Neumann FJ, et al., Intracoronary Stenting and Antithrombotic: Regimen Rapid Early Action for Coronary Treatment 2 (ISAR-REACT 2) Trial Investigators. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 2006; 295:1531-1538.
73. Smith SC Jr, Feldman TE, Hirshfeld JW Jr, et al. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 2006; 113:156-175.
74. Angiolillo DJ. Tackling the diabetic platelet: is high clopidogrel dosing the answer? J Thromb Haemost 2006; 4:2563-2565.
75. Alfonso F, Angiolillo DJ. Platelet function assessment to predict outcomes after coronary interventions: Hype or Hope? J Am Coll Cardiol 2006; 48:1751-1754.